Christos Demosthenous

G. Papanikolaou General Hospital — Greece

Medicine · Health Sciences

11h-index464citations52works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(18), Hematopoietic Stem Cell Transplantation(10), CAR-T cell therapy research(10), Lymphoma Diagnosis and Treatment(6), Acute Myeloid Leukemia Research(6)

Publications52 total

Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Other Myeloid Malignancies
Pharmaceuticals·2025Open Access
Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies
Cancers·2025· 5 citedOpen Access
Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in the Era of Quadruplets
Clinical Lymphoma Myeloma & Leukemia·2025
Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial
JCO Oncology Practice·2025
Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case–Control Study
International Journal of Molecular Sciences·2025· 1 citedOpen Access
Evaluation of Cognitive Impairment and Neurotoxicity Post CAR-T Cell Therapy.
Transplantation and Cellular Therapy·2025
Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease
Blood·2024Open Access
Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
Blood·2024· 1 cited
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
Blood·2024
Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study
Blood·2024
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
International Journal of Molecular Sciences·2024· 6 citedOpen Access
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
HemaSphere·2024· 1 citedOpen Access
EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy
Blood Vessels Thrombosis & Hemostasis·2024· 10 citedOpen Access
Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation
Transplantation Proceedings·2024· 7 citedOpen Access
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
American Journal of Hematology·2024· 10 citedOpen Access
Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
International Journal of Molecular Sciences·2023· 6 citedOpen Access
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
EClinicalMedicine·2023· 16 citedOpen Access
The evolving landscape of <scp>COVID</scp>‐19 and <scp>post‐COVID</scp> condition in patients with chronic lymphocytic leukemia: A study by <scp>ERIC</scp>, the <scp>European</scp> research initiative on <scp>CLL</scp>
American Journal of Hematology·2023· 21 citedOpen Access
Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience
Cancers·2023· 6 citedOpen Access
P1311: LONG-TERM SAFETY AND EFFICACY OF EXTRACORPOREAL PHOTOPHERESIS AS EARLY SECOND-LINE TREATMENT FOR PATIENTS WITH STEROID-DEPENDENT OR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.
HemaSphere·2023Open Access
page 1 of 3Next →

Frequent Co-authors

Ioannis Batsis(22), Eleni Gavriilaki(21), Anna Vardi(20), Ioanna Sakellari(19), Thomas Chatzikonstantinou(16), Αchilles Anagnostopoulos(16), Zoi Bousiou(16), Despina Mallouri(15), Apostolia Papalexandri(13), Lydia Scarfò(10), Alkistis Panteliadou(10), Evangelia Yannaki(10), Damianos Sotiropoulos(10), Georgios Karakatsoulis(9), Arnon P. Kater(9), Martin Šimkovič(9), Tasoula Touloumenidou(8), Michael Doubek(7), Maria Efstathopoulou(7), Alicia Enrico(7)